Source (95% CI)

Sequencing = TPM

Van_Allen, Melanoma, n = 42 -0.70 [-1.46; 0.06] Mariathasan, Lymph_node, n = 26 - 0.67 [-1.63; 0.29]-0.50 [-1.17; 0.17] Riaz, Melanoma, n = 51Mariathasan, Bladder, n = 194-0.25 [-0.60; 0.10] -0.24 [-1.20; 0.72] Snyder, Ureteral, n = 25Fumet.2, Lung, n = 43-0.16 [-0.94; 0.62] Mariathasan, Kidney, n = 670.00[-0.57; 0.57]Braun, Kidney, n = 1780.10 [-0.29; 0.49] 0.57 [-0.27; 1.41] Miao.1, Kidney, n = 33Mariathasan, Ureteral, n = 260.59 [-0.37; 1.55] -0.13 [-0.33; 0.08] Total Heterogeneity: $\chi_9^2 = 11.37 \ (P = .25), \ I^2 = 21\% \ [0\%; 61\%]$

Sequencing = FPKM

Hugo, Melanoma, n = 27-0.55 [-1.78; 0.68] 0.00 [-0.51; 0.51] Liu, Melanoma, n = 121 Nathanson, Melanoma, n = 240.18 [-0.80; 1.16] -0.03 [-0.46; 0.39] Total Heterogeneity: $\chi_2^2 = 0.87$ (P = .65), $I^2 = 0\%$ [0%; 90%] -0.11 [-0.28; 0.06] Total Heterogeneity: $\chi_{12}^2 = 12.39 \ (P = .41), \ I^2 = 3\% \ [0\%; 58\%]$ Test for overall effect: $z = -1.24 \ (P = .21)$

Test for subgroup differences: $\chi_1^2 = 0.15$ (P = .69)

0 0.5 1 logHR estimate